Learn More
10009 Background: Treatment (tx) options are limited after GIST pts develop resistance to IM and SU. SOR inhibits KIT, VEGFR, PDGFR-β, and BRAF kinases. In preclinical GIST models, SOR inhibits many(More)
4 Background: GIST pts who develop resistance to IM and SU have few therapeutic options. SOR inhibits KIT, VEGFR, PDGFR-β, and BRAF kinases. In preclinical models, SOR has activity against several(More)